Actively Recruiting
CR-CHOP+X in Previously Untreated DEL
Led by Ruijin Hospital · Updated on 2024-12-30
49
Participants Needed
1
Research Sites
207 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, single-arm, open-label phase II clinical trial that evaluates the efficacy and safety of CR-CHOP regimen combined with different targeted drugs based on different molecular subtypes in newly diagnosed DEL patients.
CONDITIONS
Official Title
CR-CHOP+X in Previously Untreated DEL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diffuse large B-cell lymphoma with CD20 positive
- MYC and BCL2 are expressed simultaneously, MYC ≥40%, BCL2 ≥50%
- Age 18 to 75 years old
- ECOG physical status score of 0, 1 or 2
- No previous history of malignant tumors or simultaneous other tumors
- Life expectancy of at least 6 months as judged by investigator
- Written informed consent provided by patient or legal representative
- International prognostic Index (IPI) score greater than 1
You will not qualify if you...
- Previously received systemic or local treatment including chemotherapy
- Previously received autologous stem cell transplantation
- Previous history of other malignant tumors except skin basal cell carcinoma and cervical carcinoma in situ
- Uncontrolled cardiovascular, cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases, or other diseases
- Primary central nervous system lymphoma
- Left ventricular ejection fraction 50% or lower
- Laboratory abnormalities at screening unrelated to lymphoma: neutrophils below 1.510^9/L, platelets below 7510^9/L, elevated liver enzymes or bilirubin above specified limits, elevated creatinine above 1.5 times upper limit
- Other uncontrolled medical conditions affecting study participation
- Mental illness or inability to comply with study protocol
- Pregnant or lactating women
- Living with HIV
- Positive HbsAg test requiring HBV DNA test and negative result before enrollment; similarly, positive HBcAb with positive HBV DNA requires negative treatment before admission
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
No. 197 Ruijin 2nd Road, Huangpu District, Shanghai
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
L
Li Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here